Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare la sicurezza e l'efficacia dell'IPN10200 nei partecipanti adulti con rughe facciali superiori da moderate a gravi (LANTIC)

2 ottobre 2026 aggiornato da: Ipsen

Uno studio di fase Ib/II, multicentrico, in doppio cieco, randomizzato, controllato con placebo, di incremento della dose e di ricerca della dose per valutare la sicurezza e l'efficacia dell'IPN10200 nel migliorare l'aspetto delle rughe della parte superiore del viso da moderate a gravi negli adulti

The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.

This study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants.

Stage 1 (phase Ib & II)

  • Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL)
  • Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport
  • Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study).

Stage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL)

Stage 3 (phase II)

- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

727

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Antibes, Francia
        • MEDITI - Clinique Del Mar
      • Lyon, Francia
        • Aimed S.A.S
      • Paris, Francia
        • Clinique de Chirurgie Esthétique Iéna
      • Berlin, Germania, 13353
        • CRS Clinical Research Services Berlin GMBH
      • Berlin, Germania
        • Interdisciplinary Study Association
      • Darmstadt, Germania
        • ROSENPARK RESEARCH GmbH
      • Düsseldorf, Germania
        • Privatpraxis Dr. Hilton & Partner
      • Hamburg, Germania
        • Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft
      • Mahlow, Germania
        • Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow
    • State of Berlin
      • Kassel, State of Berlin, Germania
        • Interdisciplinary Study Association

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
  2. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the ILA using a validated 4-point photographic scale.
  3. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the SSA using a validated 4-point categorical scale.
  4. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  5. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  6. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction as assessed by the SSA using a 4-point photographic scale.
  7. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction, as assessed by the SSA using a 4-point photographic scale.
  8. Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines (Stages 1 to 3) at Baseline, as assessed by the SLS.
  9. Male and female participants (only female for Stage 1/Step 1). Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  10. Capable of giving signed informed consent includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  11. Participant has both the time and the ability to complete the study and comply with study instructions.
  12. Does not reside in an institution by administrative or court order.
  13. Is not a sponsor employee or clinical research unit personnel directly affiliated with the study or is not an immediate family member. Immediate family is defined as a spouse, parent, child or sibling whether biological or legally adopted.

Exclusion Criteria:

  1. An active infection or other skin problems in the upper face including the GL, FHL, and LCL area (e.g. acute acne lesions or ulcers).
  2. A history of eyelid blepharoplasty or brow lift within the past 5 years
  3. A history of facial nerve palsy.
  4. Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  5. Any known medical condition that may put the participant at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.)
  6. Has COVID-19 illness or a known positive SARS-CoV-2 test (Stage 1), or the presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function)
  7. Previous treatment with any BoNT serotype for Stage 1 / Step 1 or any recent treatment (within the past 9 months prior to baseline) with any BoNT serotype for Stage 1 / Step 2, Stage 1/Step 3, Stages 2 and 3. Participants treated in earlier Stages/Steps of the study must not be included in any later Stages/Steps.
  8. Any prior treatment with permanent fillers in the upper face including the GL, FHL and LCL area.
  9. Any prior treatment with long lasting dermal fillers or any permanent procedures in the upper face inclusion the GL area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the 12 months prior to Baseline.
  10. Any planned facial cosmetic surgery during the study.
  11. Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention. Therapy considered necessary for the participant's welfare may be given at the discretion of the investigator.
  12. Use of medications that affect neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases, aminoglycoside antibiotics and systemic retinoids, within the past 30 days prior to baseline are prohibited or a longer washout period of at least five half-lives might be required, as deemed appropriate by the investigator for longer-acting medications. Topical use of for example aminoglycoside medications or topical retinoids on the face apart from the area of injection would be acceptable.
  13. Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the halflife is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
  14. Known positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.
  15. Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study
  16. An inability to substantially lessen GL and/or horizontal forehead rhytids even by physically spreading them apart as determined by the investigator.
  17. Known allergy or hypersensitivity to BoNT or any excipients of IPN10200 or Dusport/Azzalure, or allergy to cow's milk protein.
  18. A history of drug or alcohol abuse
  19. Pregnant women, nursing women, premenopausal women or women of childbearing potential not willing to practice a highly effective form of contraception method
  20. Male participants who are not vasectomized and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation.
  21. Any uncontrolled systemic disease or other significant medical condition which would be harmful for the participant to be entered into the study or continue participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Gruppo Dysport (solo stadio 1 / passaggio 2 e 3)

Single administration of study intervention in stage 1 / step 2 and 3 only

Sperimentale: Corabotase group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 (Corabotase:placebo)in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase: placebo:dysport) The decision to escalate to the next dose for each cohort will be based on DMC recommendation .

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.

Stage 1: Several different doses will be administrated in a dose-escalation manner.

One single injection will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

Comparatore placebo: Placebo group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase:Corabotase: placebo) The decision to escalate to the next dose for each cohort will be based on DMC recommendation.

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.(Corabotase:placebo)

Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of treatment emergent adverse events (TEAEs) at each dose
Lasso di tempo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of serious adverse events (SAEs) at each dose
Lasso di tempo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
Lasso di tempo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Response to treatment at Stage 2 for the FHL group
Lasso di tempo: At Week 4

Measured by the composite response of ≥ 2-grade improvement on Investigator's Live Assessment (ILA) and subject's self-assessment (SSA) at maximum contraction on the forehead lines:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the Forehead Lines (FHL) at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL group
Lasso di tempo: At Week 4

Measured by the composite response of ≥ 2-grade improvement on ILA and SSA at maximum contraction on the forehead lines (FHL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs and FHLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs and FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the LCL group
Lasso di tempo: At Week 4

Measured by the composite response of ≥ 2-grade improvement ILA and SSA at maximum contraction on both sides of the lateral canthal lines (LCL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the LCLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their LCLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
Lasso di tempo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readings
Lasso di tempo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.
Lasso di tempo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Risposta al trattamento ottenuta con un punteggio di "molto soddisfatto" o "soddisfatto" sul livello di soddisfazione del soggetto (SLS)
Lasso di tempo: Dal basale alla fine dello studio (9 mesi)
Dal basale alla fine dello studio (9 mesi)
Percentage of participants response to treatment.
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Measured by the composite response of ≥ 2-grade improvement on ILA and SSA for each concerned facial area in each respective stage (GL/LCL/FHL)

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs/LCLs/FHLs in each respective stage at maximum frown and at rest where 0 is "no lines are noticeable" and 3 is "lines are extremely pronounced"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs/LCLs/FHLs in each respective stage at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the ILA at maximum contraction for each concerned facial area
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at rest on each facial area
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the SSA at maximum contraction for each concerned facial area
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the SSA at maximum contraction for each concerned facial area.
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

Stage 2 and Stage 3.

From the baseline to the end of the study (up to 6 years, 5 months)
Duration of treatment response based on ILA and SSA at maximum contraction for each concerned facial area
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Time to onset of treatment response based on subject diary cards to evaluate the appearance of their lines for each concerned facial area
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by Facial Appearance Overall scale score on the Face-Q satisfaction scale
Lasso di tempo: From the baseline to the end of the study (up to 6 years, 5 months)

Stage 3. Face Q is a participant-reported outcome instrument to evaluate the experience and outcomes of aesthetic facial procedures from the participant's perspective. The Face Q instrument is composed of over 40 scales, covering four domains (Satisfaction with Facial Appearance, Health Related Quality of Life, Adverse Effects, and Process of Care).

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by FACE-Q Short Form Facial Appearance scale score.
Lasso di tempo: From the baseline to the end of the study (6 years, 5 months)

Stage 3. The FACE-Q Short Form Facial Appearance scale is a participant-reported outcome instrument. It asks how dissatisfied or satisfied the participant is with their upper facial lines (UFL) (GL+FHL+LCL). The scale ranges from very dissatisfied to very satisfied.

From the baseline to the end of the study (6 years, 5 months)
Incidence, severity and nature of treatment emergent adverse events (TEAEs)
Lasso di tempo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of serious adverse events (SAEs)
Lasso di tempo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
Lasso di tempo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
Lasso di tempo: From baseline to the end of the study (6 years, 5 months)

All stages (except Stage 1/Step 1). Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From baseline to the end of the study (6 years, 5 months)
Time between two consecutive injections
Lasso di tempo: From baseline to the end of the study (up to 6 years, 5 months)

Stage 1/Step 3 .

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with binding antibodies to IPN10200
Lasso di tempo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to IPN10200
Lasso di tempo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with binding antibodies to BontA
Lasso di tempo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to BontA
Lasso di tempo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Ipsen Medical Director, Ipsen

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 aprile 2021

Completamento primario (Stimato)

19 agosto 2027

Completamento dello studio (Stimato)

19 agosto 2027

Date di iscrizione allo studio

Primo inviato

26 marzo 2021

Primo inviato che soddisfa i criteri di controllo qualità

26 marzo 2021

Primo Inserito (Effettivo)

29 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • D-FR-10200-002
  • 2024-512782-14-00 (Ctis)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Periodo di condivisione IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Criteri di accesso alla condivisione IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .